2024
TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL
Lugogo N, Chupp G, Corren J, Israel E, Molfino N, Martin N, Spahn J, Ambrose C. TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL. Annals Of Allergy Asthma & Immunology 2024, 133: s53-s54. DOI: 10.1016/j.anai.2024.08.184.Peer-Reviewed Original ResearchInflammatory biomarker levelsBaseline biomarker levelsBiomarker levelsPost hoc pooled analysisEffect of tezepelumabBaseline to weekLevels of FeNOSerum total IgESerum total IgE.Absolute percentage changeIncreased levelsDouble-blindPlacebo-controlledTezepelumabTotal IgEInflammatory biomarkersParallel-groupUncontrolled asthmaFeNOPatientsPercentage changeBiomarkersPlaceboWeeksBaselineEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Carr T, Moore W, Kraft M, Brusselle G, Castro M, Chupp G, Wechsler M, Hunter G, Lindsley A, Llanos J, Burke L, Chandarana S, Ambrose C. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances In Therapy 2024, 41: 2978-2990. PMID: 38802635, PMCID: PMC11213736, DOI: 10.1007/s12325-024-02889-8.Peer-Reviewed Original ResearchAnnualized asthma exacerbation rateClinically relevant subgroupsEfficacy of tezepelumabBaseline patient characteristicsUncontrolled asthmaClinically relevant subgroups of patientsPatient characteristicsStandard-of-care therapyRelevant subgroups of patientsTezepelumab reduced exacerbationsRelevant subgroupsPlacebo-controlled studyAsthma exacerbation rateSubgroup of patientsReducing asthma exacerbationsBody mass indexPost hoc analysisNSAID sensitivityDouble-blindExacerbation rateTezepelumabSmoking historyPatient subgroupsPlaceboIntroductionMany patients
2023
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
MOORE W, LUGOGO N, CHUPP G, MARTIN N, AMBROSE C, COOK W, ACKERT J. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2023, 164: a4-a7. DOI: 10.1016/j.chest.2023.07.073.Peer-Reviewed Original ResearchLONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
CHUPP G, LUGOGO N, WECHSLER M, LAWSON K, LINDSLEY A, SPAHN J, AMBROSE C. LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX. CHEST Journal 2023, 164: a9-a14. DOI: 10.1016/j.chest.2023.07.075.Peer-Reviewed Original ResearchEfficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose C, Hellqvist Å, Roseti S, Molfino N, Llanos J, Martin N, Bowen K, Griffiths J, Parnes J, Colice G. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal Of Respiratory And Critical Care Medicine 2023, 208: 13-24. PMID: 37015033, PMCID: PMC10870853, DOI: 10.1164/rccm.202210-2005oc.Peer-Reviewed Original ResearchConceptsAsthma exacerbation rateUncontrolled asthmaExacerbation rateSecondary outcomesClinical trialsOverall populationRelevant subgroupsMeaningful reductionEfficacy of tezepelumabExacerbation-related hospitalizationsSafety of tezepelumabPlacebo-controlled trialEmergency department visitsInflammatory biomarker levelsNitric oxide levelsAdverse eventsAllergy statusBaseline bloodClinical characteristicsDepartment visitsPooled analysisNAVIGATOR trialBiomarker levelsOxide levelsTezepelumabEffect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti S, Ambrose C, Llanos J, Cook B, Corren J, Colice G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study. Annals Of Allergy Asthma & Immunology 2023, 131: 343-348.e2. PMID: 37263380, DOI: 10.1016/j.anai.2023.05.028.Peer-Reviewed Original ResearchConceptsExacerbation-related hospitalizationsHealthcare utilizationUncontrolled asthmaNAVIGATOR studyAsthma-related healthcare utilizationEffect of tezepelumabPatient healthcare utilizationRecipients of placeboThymic stromal lymphopoietinHealth-related qualityIntensive care daysHuman monoclonal antibodySubcutaneous tezepelumabAsthma controlAsthma exacerbationsLung functionSpecialist visitsEmergency departmentCare daysOverall burdenTezepelumabMAIN OUTCOMEPlaceboAmbulance transportHospitalizationEfficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study
Kraft M, Chupp G, Reeh K, Lindsley A, Cook B, Hunter G, Ambrose C. Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study. 2023, a4751-a4751. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4751.Peer-Reviewed Original Research
2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
Corren J, Wechsler M, Chupp G, Roseti S, Hellqvist Å, Martin N, Llanos J, Ambrose C, Colice G. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 943-945.e2. PMID: 36375743, DOI: 10.1016/j.jaip.2022.10.042.Peer-Reviewed Original ResearchEFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES
CORREN J, WECHSLER M, CHUPP G, AMBROSE C, ROSETI S, HELLQVIST Å, ACKERT J, MARTIN N, COLICE G. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2022, 162: a21-a22. DOI: 10.1016/j.chest.2022.08.018.Peer-Reviewed Original Research
2021
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY
Chupp G, Menzies-Gow A, Ambrose C, Cook W, Kmita K, Lindsley A, Llanos-Ackert J, Colice G, Lugogo N. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY. CHEST Journal 2021, 160: a37-a40. DOI: 10.1016/j.chest.2021.07.078.Peer-Reviewed Original ResearchEffect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR
Korn S, Bourdin A, Chupp G, Colice G, Ambrose C, Kmita K, Llanos-Ackert J, Molfino N, Cook B. Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR. 2021, oa1198. DOI: 10.1183/13993003.congress-2021.oa1198.Peer-Reviewed Original ResearchReductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study
Bourdin A, Menzies-Gow A, Chupp G, Israel E, Hellqvist, Hunter G, Ambrose C, Llanos Ackert J, Colice G, Cook B, Corren J. Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study. 2021, a1203-a1203. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1203.Peer-Reviewed Original ResearchEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study
Corren J, Bourdin A, Chupp G, Israel E, Ambrose C, Llanos Ackert J, Kmita K, Cook B, Colice G, Menzies-Gow A. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study. 2021, a1198-a1198. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1198.Peer-Reviewed Original ResearchEfficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Griffiths J, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study. Journal Of Allergy And Clinical Immunology 2021, 147: ab249. DOI: 10.1016/j.jaci.2020.12.050.Peer-Reviewed Original Research